Time-Course of Arm Lymphedema and Potential Risk Factors for Progression of Lymphedema After Breast Conservation Treatment for Early Stage Breast Cancer
- 5 April 2012
- journal article
- research article
- Published by Hindawi Limited in The Breast Journal
- Vol. 18 (3), 219-225
- https://doi.org/10.1111/j.1524-4741.2012.01229.x
Abstract
The objective of this study was to describe the progression of arm lymphedema (ALE) after the initial presentation among patients receiving breast conservation therapy for early stage breast cancer and to identify potential risk factors contributing to ALE progression. The study sample was the 266 stage I or II breast cancer patients with documented ALE who underwent breast conservation therapy that included lumpectomy, axillary staging followed by radiation therapy. ALE were graded according to a difference of 0.5–2 cm (mild), 2.1–3 cm (moderate), and >3 cm (severe) in the circumference between the upper extremities for the treated and untreated sides. ALE at presentation was scored as mild, moderate, and severe in 109 (41%), 125 (47%), and 32 (12%) patients, respectively. One third of patients with ALE progressed to a more severe grade of lymphedema at 5 years of follow-up. Age older than 65 years at the time of breast cancer treatment was associated with higher risk of ALE progression when compared 65 year age or younger (p = 0.04). The patients who had regional lymph node irradiation including posterior axillary boost were at higher risk of lymphedema progression than the patients treated with whole breast irradiation only (p = 0.001). Progression of ALE is a common occurrence. The current study provides support for the utility of routine arm measurements after breast cancer treatment to facilitate timely diagnosis and treatment of ALE.Keywords
This publication has 27 references indexed in Scilit:
- Risk Factors for Lymphedema after Breast Cancer TreatmentCancer Epidemiology, Biomarkers & Prevention, 2010
- Balancing Lymphedema RiskExercise and Sport Sciences Reviews, 2010
- Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patientsCancer, 2009
- Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary BehaviorsJournal of Clinical Oncology, 2008
- Efficacy of complete decongestive therapy and manual lymphatic drainage on treatment-related lymphedema in breast cancerInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled studyThe Lancet Oncology, 2006
- Breast Cancer-Related Lymphedema ? What Are the Significant Predictors and How They Affect the Severity of Lymphedema?The Breast Journal, 2006
- Predictive Factors of Response to Intensive Decongestive Physiotherapy in Upper Limb Lymphedema After Breast Cancer Treatment: a Cohort StudyBreast Cancer Research and Treatment, 2006
- Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC TrialJNCI Journal of the National Cancer Institute, 2006
- Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group TrialAnnals of Surgical Oncology, 2006